OrthoPediatrics

Pediatric orthopedic implants and instruments provider

OrthoPediatrics

Pediatric orthopedic implants and instruments provider

Overview

OrthoPediatrics designs, develops, and markets anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions. Its products—over 70 systems for trauma and deformity correction—are tailored to pediatric anatomy and growth, and are sold to hospitals and surgical centers through a collaborative process with surgeons. The company differentiates itself by focusing exclusively on pediatric orthopedics, building a defensible niche with a global presence (US, UK, Israel) to address the unique needs of growing patients. Its goal is to provide targeted medical devices that improve outcomes for pediatric patients and to expand its international footprint as the leading specialized supplier in pediatric orthopedic devices.

Work here?Claim your company

About OrthoPediatrics

Simplify's Rating

Why OrthoPediatrics is rated

B-

Rated B on Competitive Edge

Rated B on Growth Potential

Rated C on Differentiation

Industries

Industrial & ManufacturingHealthcare

Company Size

201-500

Company Stage

IPO

Headquarters

Warsaw, IN

Founded

2006

Get referred to OrthoPediatrics

See people who can refer or advise you

Simplify's take

What believers are saying

October 27, 2026 revenue rose 19% to $72.7 million; guidance increased to $270 million-$273 million.
Q3 2026 free cash flow turned positive at $1.6 million, signaling operating leverage.
The SpineCorporation acquisition and over 60 OPSB clinics expand bracing distribution and recurring surgeon relationships.

What critics are saying

September 2026 cash was $44.9 million against $98 million of debt and notes.
Fourth-quarter 2026 guidance stays below Q3 sales, exposing dependence on Brazil and 7D timing.
If 2027 launches slip, refinancing pressure and persistent GAAP losses can crush shareholder value.

What makes OrthoPediatrics unique

OrthoPediatrics sells only pediatric orthopedic implants, braces, and instruments, unlike diversified rivals.
October 2026 FDA-cleared PNP Retrograde extends its surgeon-designed PNP platform into femur trauma.
The 3P Hip, 3P Mini, and OPSB products create a pediatric-specific product moat.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$356.4M

Above

Industry Average

Funded Over

7 Rounds

Post IPO Debt funding comparison data is currently unavailable. We're working to provide this information soon!

Post IPO Debt Funding Comparison Coming Soon

Stock Price

Growth & Insights and Company News

6 month growth

1 year growth

-1%

2 year growth

Yahoo Finance

Oct 28th, 2026

OrthoPediatrics Q3 revenue rises 19% to $72.7M, and it raises 2026 guidance to $270M–$273M

OrthoPediatrics (NASDAQ:KIDS) posted record third-quarter revenue of $72.7 million, up 19% from $61.2 million a year earlier. Growth came from trauma, deformity, scoliosis and specialty bracing products. Adjusted EBITDA hit a record $6.9 million. The net loss narrowed to $0.25 per share from $0.50. The company raised its 2026 revenue guidance to $270 million–$273 million, implying 14% to 16% growth. It kept its adjusted EBITDA target of about $25 million and expects free cash flow to break even or better. Chief executive officer David Bailey said the existing portfolio continues to deliver, with new product launches ahead. Its bracing business grew more than 20% and now has over 60 clinics.

Yahoo Finance

Oct 27th, 2026

OrthoPediatrics wins FDA clearance for PNP Retrograde femur nail and completes first implantations

OrthoPediatrics (Nasdaq: KIDS) has received US Food and Drug Administration clearance for its Pediatric Nailing Platform (PNP) Femur Retrograde Nail System, and has completed the first procedures using it. The system was developed with pediatric orthopedic surgeons and designed for children's anatomy. It includes anatomic nails for trauma and straight nails for deformity, in diameters from 7mm to 11mm. New instruments are meant to simplify complex corrective procedures. The platform has supported nearly 15,000 patients worldwide, said Joe Hauser. He said the first surgical case is complete and early adoption is encouraging. The system will have a limited market release for the rest of 2026, with broader commercialisation planned for 2027.

MarketScreener

Oct 7th, 2026

OrthoPediatrics Corp. launches OPSB(R) Knee 'TractorFIX contracture management orthosis.

OrthoPediatrics Corp. launches OPSB(R) Knee 'TractorFIX contracture management orthosis. Published on 10/07/2026 at 09:20 am EDT S&P Capital IQ OrthoPediatrics Corp. announced the expansion of its OrthoPediatrics Specialty Bracing (?OPSB?) portfolio with a new product launch, the OPSB(R) Knee 'TractorFIX contracture management orthosis. Knee 'TractorFIX is a first-of-its-kind pediatric bracing solution intended to treat knee contractures, pre-existing or developing, in pediatric patients approximately 2 to 21 years of age who are undergoing tibial treatment with an external fixator. The brace connects directly to the external fixator to support contracture management during tibial treatment. The bracing system was developed to address the significant clinical challenges caused by pediatric knee contractures, which can include limited range of motion, complicated rehabilitation, prolonged treatment, and negatively impacted functional outcomes. Knee 'TractorFIX expands OPSB's lower extremity bracing portfolio while addressing a clinical indication with limited pediatric-specific options. The bracing system adds to a growing offering of specialty bracing technologies, including products such as DF2(R), TRAXIO, and PediHip(R). (C) S&P Capital IQ - 2026

Yahoo Finance

Oct 7th, 2026

OrthoPediatrics launches OPSB Knee 'TractorFIX brace for pediatric knee contractures

OrthoPediatrics Corp. has launched OPSB Knee 'TractorFIX, a new bracing system designed to treat knee contractures in paediatric patients aged 2 to 21 undergoing tibial treatment with an external fixator. The brace connects directly to the external fixator to support contracture management during treatment. The product addresses clinical challenges including limited range of motion, complicated rehabilitation, and prolonged treatment. It offers a standardised, paediatric-focused alternative to custom-built solutions that are time-intensive to make and fit. The launch expands OrthoPediatrics' lower extremity bracing portfolio, which includes products such as DF2, TRAXIO, and PediHip. Founded in 2006, OrthoPediatrics markets over 90 systems across trauma and deformity, scoliosis, and sports medicine categories in the United States and over 75 countries.

Yahoo Finance

Aug 25th, 2026

OrthoPediatrics launches 3P Hip System after 350+ successful implantations

OrthoPediatrics Corp. has launched its 3P Pediatric Plating Platform Hip System across the United States following a successful limited release. The system saw over 350 surgical implantations during its initial phase, demonstrating strong demand for the pediatric-specific hip plating technology. The 3P Hip System is the first product in OrthoPediatrics' broader Pediatric Plating Platform portfolio. It features locking proximal femur plates and beam screw constructs in infant, child, and adolescent configurations for treating proximal femur trauma and deformities. The system was developed through collaboration between OrthoPediatrics and leading pediatric orthopaedic surgeons. It aims to modernise plating through advanced implant and instrumentation technologies, offering enhanced fixation options and streamlined workflow. OrthoPediatrics plans to release additional Pediatric Plating Platform systems to expand its trauma and deformity correction portfolio.

Recently Posted Jobs